Human medicines European public assessment report (EPAR): Saphnelo, anifrolumab, Lupus Erythematosus, Systemic, Date of authorisation: 14/02/2022, Revision: 3, Status: Authorised

Aldesleukin : List of nationally authorised medicinal products - PSUSA/00000076/202212

Human medicines European public assessment report (EPAR): Zubsolv, buprenorphine,naloxone, Opioid-Related Disorders, Date of authorisation: 10/11/2017, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Esophageal Squamous Cell Carcinoma, Date of authorisation: 15/09/2023, Status: Authorised

Human medicines European public assessment report (EPAR): Dupixent, dupilumab, Dermatitis, Atopic;Prurigo;Esophageal Diseases;Asthma;Sinusitis, Date of authorisation: 26/09/2017, Revision: 30, Status: Authorised

Innovation in medicines

Human medicines European public assessment report (EPAR): Reblozyl, luspatercept, Anemia;Myelodysplastic Syndromes;beta-Thalassemia, Date of authorisation: 25/06/2020, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Tezspire, tezepelumab, Asthma, Date of authorisation: 19/09/2022, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Bortezomib Hospira, bortezomib, Multiple Myeloma, Date of authorisation: 22/07/2016, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Rybelsus, semaglutide, Diabetes Mellitus, Type 2, Date of authorisation: 03/04/2020, Revision: 6, Status: Authorised